硕迪生物股价连续下跌，GLP-1赛道竞争加剧引关注

Core Viewpoint - The stock price of Shuo Di Bio (GPCR.OQ) has been on a continuous decline over the past week, despite a recent non-exclusive patent licensing agreement with Roche and Genentech that provided $100 million in upfront payment [1][2]. Stock Performance - As of February 13, the stock closed at $70.07, down 2.73% for the day, with a cumulative decline of 6.47% over the past five days and a price range fluctuation of 14.95%, hitting a low of $69.95 [1]. - Trading volume varied, with a peak of $64.05 million on February 12 (turnover rate of 1.24%) and a decrease to $89.24 million on February 13 (turnover rate of 1.77%) [1]. - The biotechnology sector rose by 1.32% during the same period, but the individual stock underperformed compared to the Nasdaq index, which fell by 0.22% [1]. Recent Events - On December 30, 2025, Shuo Di Bio entered into a non-exclusive patent licensing agreement with Roche and Genentech, securing $100 million in upfront payment and the right to receive low single-digit royalties on future sales of the oral GLP-1 drug CT-996 [2]. - Despite this positive development, the stock price has reacted negatively due to sector rotation, technical corrections, and increased competition concerns in the GLP-1 market [2]. Financial Analysis - For the third quarter of 2025, the company reported zero revenue and a net loss of $65.8 million, with a return on equity (ROE) of -25.31% [3]. - Ongoing research and development expenditures are putting pressure on short-term profitability, but the company maintains a relatively stable financial structure with a debt-to-asset ratio of 7.47% and a current ratio of 14.15% [3]. Institutional Perspectives - Several brokerages express long-term optimism regarding Shuo Di Bio's cash flow potential from the patent collaboration and the scarcity of its oral GLP-1 pipeline [4]. - However, short-term stock performance is constrained by market sentiment fluctuations, profit-taking pressures in the sector, and a low liquidity environment that amplifies volatility [4].